In a study involving over 500 children, artificial intelligence using echocardiography demonstrated accuracy comparable to expert cardiologists in detecting rheumatic heart disease, hinting at the prospect of a potentially transformative tool for early intervention and disease prevention.
After adjusting for confounders, data revealed higher levels of obesity indices were linked with a gradual and dose-dependent increase in urate levels.
Findings revealed an elevation of educational attainment by one standard deviation exhibited a protective effect against gout.
Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.
How well do patients with rheumatoid arthritis adhere to treatment with a TNF inhibitor and how likely and long lasting is remission? Test your knowledge with this quiz.
A review of 15 RCTS suggests that both electroacupuncture and conventional drugs demonstrate similar effectiveness in addressing pain for patients with acute gouty arthritis.
Gout incidence rate significantly increased after relieving urinary tract obstruction.
Mortality risks in gout have not improved in the United States in the past 3 decades, with a similar risk found among contemporary cases of gout in the United Kingdom.
There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.
In a new study, 31.9% of individuals with osteoporosis had depressive symptoms and 10% had probable depression.
Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.
On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.
Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.
Benign prostatic hyperplasia was 1.13-fold higher in those with gout when compared with controls.
Patients with gout had a 1.26-fold higher likelihood of experiencing migraines when compared with those without gout.
A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.
Compared to routine care, TCMD could better reduce the incidence of adverse events and the level of laboratory indicators.
Significant differences in the practice of primary healthcare physicians were observed based on medical specialty when treating and managing asymptomatic hyperuricemia and gout.
As gastrointestinal (GI) symptoms are common in the US, how does rheumatoid arthritis (RA) affect the frequency of GI events? Test your knowledge with this quiz.
Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.
Entering menopause prior to age 45 was associated with a 46% increased risk of developing RA compared with those who began menopause at ≥50 years.
Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.
Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.
Results indicated patients with GERD are at a 69% increased risk of developing RA.
A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.
The PETRA questionnaire proves valuable in assessing the transition readiness of juvenile idiopathic arthritis patients into adult care, with a focus on self-management skills.
The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.
BLA submission was based on data from phase 3 clinical trials in which DMB-3115 showed no clinically meaningful differences compared with the reference product for the treatment of plaque psoriasis.
Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.
Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.
